Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I, Romagnoli D, Galardi F, De Luca F, Biagioni C, Curigliano G, Criscitiello C, Minisini AM, Moretti E, Risi E, Guarducci C, Nardone A, Biganzoli L, Benelli M, Malorni L. Migliaccio I, et al. Among authors: galardi f. JCO Precis Oncol. 2024 Feb;8:e2300285. doi: 10.1200/PO.23.00285. JCO Precis Oncol. 2024. PMID: 38427931 Clinical Trial.
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.
McCartney A, Bonechi M, De Luca F, Biagioni C, Curigliano G, Moretti E, Minisini AM, Bergqvist M, Benelli M, Migliaccio I, Galardi F, Risi E, De Santo I, Romagnoli D, Biganzoli L, Di Leo A, Malorni L. McCartney A, et al. Among authors: galardi f. Clin Cancer Res. 2020 May 1;26(9):2131-2139. doi: 10.1158/1078-0432.CCR-19-3271. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937617 Free article. Clinical Trial.
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Galardi F, De Luca F, Biagioni C, Migliaccio I, Curigliano G, Minisini AM, Bonechi M, Moretti E, Risi E, McCartney A, Benelli M, Romagnoli D, Cappadona S, Gabellini S, Guarducci C, Conti V, Biganzoli L, Di Leo A, Malorni L. Galardi F, et al. Breast Cancer Res. 2021 Mar 24;23(1):38. doi: 10.1186/s13058-021-01415-w. Breast Cancer Res. 2021. PMID: 33761970 Free PMC article. Clinical Trial.
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.
Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, Guarducci C, Boccalini G, Gabellini S, Migliaccio I, Di Leo A, Pestrin M, Malorni L. Bonechi M, et al. Among authors: galardi f. Oncotarget. 2018 Mar 27;9(23):16389-16399. doi: 10.18632/oncotarget.24700. eCollection 2018 Mar 27. Oncotarget. 2018. PMID: 29662653 Free PMC article.
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart M, Gradishar WJ, Chia S, Di Leo A, Malorni L. McCartney A, et al. Among authors: galardi f. Eur J Cancer. 2019 Jun;114:55-66. doi: 10.1016/j.ejca.2019.04.002. Epub 2019 May 3. Eur J Cancer. 2019. PMID: 31059974 Clinical Trial.
Cell-Free DNA-Methylation-Based Methods and Applications in Oncology.
Galardi F, Luca F, Romagnoli D, Biagioni C, Moretti E, Biganzoli L, Leo AD, Migliaccio I, Malorni L, Benelli M. Galardi F, et al. Biomolecules. 2020 Dec 15;10(12):1677. doi: 10.3390/biom10121677. Biomolecules. 2020. PMID: 33334040 Free PMC article. Review.
32 results